BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/4/2014 3:52:00 PM | Browse: 405 | Download: 298
Publication Name World Journal of Gastroenterology
Manuscript ID 5049
Country of Manuscript Source Italy
2013-08-12 11:23
Peer-Review Started
2013-08-12 15:35
To Make the First Decision
2013-09-02 16:20
Return for Revision
2013-09-05 14:14
Second Decision
2013-12-13 13:57
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-12-13 14:44
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-12-31 15:06
Publish the Manuscript Online
2014-01-19 14:17
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Oncology
Manuscript Type Minireviews
Article Title Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment
Manuscript Source Invited Manuscript
All Author List Girolamo Ranieri, Ilaria Marech, Vito Lorusso, Veronica Goffredo, Angelo Paradiso, Domenico Ribatti and Cosmo Damiano Gadaleta
Funding Agency and Grant Number
Corresponding author Girolamo Ranieri, MD, Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, Cancer Institute “Giovanni Paolo Ⅱ”, Via Orazio Flacco 65, 70124 Bari, Italy. giroran@tiscalinet.it
Keywords Hepatocellular carcinoma; Molecular targeting agents; Angiogenesis; Chemoembolization therapeutic; Radiofrequency treatment; Sorafenib
Core Tip The outcome of patients (with early or intermediate stage according to Barcelona Clinic Liver Cancer) treated with loco-regional approach alone [radiofrequency ablation (RFA) or transarterial chemoembolization (TACE)] is disappointing because the rebound of vascular endothelia growth factors induced by tissue hypoxia. On this basis there is a strong preclinical background to associate TACE or RFA with anti-angiogenic agents. We summarized the crucial role of angiogenesis and the pathways involved in hepatocellular cancer progression, underscoring the consequences of pro- and anti-angiogenic factors produced after loco-regional therapy. We explored preclinical and clinical results of trials combining molecular targeting agents plus TACE or RFA.
Publish Date 2014-01-19 14:17
Citation Ranieri G, Marech I, Lorusso V, Goffredo V, Paradiso A, Ribatti D, Gadaleta CD. Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World J Gastroenterol 2014; 20(2): 486-497
Url http://www.wjgnet.com/1007-9327/full/v20/i2/486.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i2.486
Full Article (PDF) WJG-20-486.pdf
Full Article (Word) WJG-20-486.doc
Manuscript File 5049-Review.docx
Answering Reviewers 5049-Answering reviewers.pdf
Copyright License Agreement 5049-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 5049-Language certificate.pdf
Peer-review Report 5049-Peer reviews.pdf
Scientific Editor Work List 5049-Scientific editor work list.doc